(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma

Breast Cancer Research

Volumn 12, Issue 1, 2010, Pages

  Luo, Ting ^a   Wang, Jiao ^b   Yin, Yancun ^a   Hua, Hui ^a   Jing, Jing ^a   Sun, Xiangming ^a   Li, Minjing ^a   Zhang, You ^a   Jiang, Yangfu ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; GLUCOSE REGULATED PROTEIN 78; LEVO EPIGALLOCATECHIN GALLATE; PACLITAXEL; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; CATECHIN; DRUG DERIVATIVE; HEAT SHOCK PROTEIN; MOLECULAR CHAPERONE GRP78;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER TISSUE; CELL LYSATE; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CATECHIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PACLITAXEL;

EID: 77956038678     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2473     Document Type: Article

References (51)

1. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014. 10.1056/NEJM199504133321507, 7885406.
2. Arnal I, Wade RH. How does taxol stabilize microtubules?. Curr Biol 1995, 5:900-908. 10.1016/S0960-9822(95)00180-1, 7583148.
3. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989, 111:273-279.
4. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667. 10.1038/277665a0, 423966.
5. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992, 13:134-136. 10.1016/0165-6147(92)90048-B, 1350385.
6. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, Cunnion RE, Reed E. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994, 86:18-24. 10.1093/jnci/86.1.18, 7505830.
7. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993, 11:1943-1951.
8. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000, 18:724-733.
9. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996, 14:1858-1867.
10. Yang CS. Inhibition of carcinogenesis by tea. Nature 1997, 389:134-135. 10.1038/38154, 9296488.
11. Suganuma M, Okabe S, Sueoka N, Sueoka E, Matsuyama S, Imai K, Nakachi K, Fujiki H. Green tea and cancer chemoprevention. Mutat Res 1999, 428:339-344.
12. Mukhtar H, Ahmad N. Mechanism of cancer chemopreventive activity of green tea. Proc Soc Exp Biol Med 1999, 220:234-238. 10.1046/j.1525-1373.1999.d01-40.x, 10202395.
13. Hibasami H, Achiwa Y, Fujikawa T, Komiya T. Induction of programmed cell death (apoptosis) in human lymphoid leukemia cells by catechin compounds. Anticancer Res 1996, 16:1943-1946.
14. Paschka AG, Butler R, Young CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett 1998, 130:1-7. 10.1016/S0304-3835(98)00084-6, 9751250.
15. Otsuka T, Ogo T, Eto T, Asano Y, Suganuma M, Niho Y. Growth inhibition of leukemic cells by (-)-epigallocatechin gallate, the main constituent of green tea. Life Sci 1998, 63:1397-1403. 10.1016/S0024-3205(98)00406-8, 9952285.
16. Qanungo S, Das M, Haldar S, Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005, 26:958-967. 10.1093/carcin/bgi040, 15705601.
17. Chen C, Shen G, Hebbar V, Hu R, Owuor ED, Kong AN. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis 2003, 24:1369-1378. 10.1093/carcin/bgg091, 12819184.
18. Roy AM, Baliga MS, Katiyar SK. Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther 2005, 4:81-90.
19. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007, 67:9809-9816. 10.1158/0008-5472.CAN-07-0625, 17942911.
20. Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG, Petasis NA, Chen TC, Schonthal AH. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113:5927-5937. 10.1182/blood-2008-07-171389, 19190249.
21. Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, Bode AM, Dong Z. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 2006, 66:9260-9269. 10.1158/0008-5472.CAN-06-1586, 16982771.
22. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006, 6:45-54. 10.2174/156652406775574523, 16472112.
23. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007, 67:3496-3499. 10.1158/0008-5472.CAN-07-0325, 17440054.
24. Wang J, Yin Y, Hua H, Li M, Luo T, Xu L, Wang R, Liu D, Zhang Y, Jiang Y. Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response. J Cell Mol Med 2009, DOI: 10.1111/j.1582-4934.2009.00873.x..
25. Mhaidat NM, Thorne R, Zhang XD, Hersey P. Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma. Apoptosis 2008, 13:1505-1512. 10.1007/s10495-008-0276-8, 18989785.
26. Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, Rosengren RJ. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer 2008, 99:1056-1063. 10.1038/sj.bjc.6604634, 2567064, 18797454.
27. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 2001, 7:3613-3624.
28. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981, 91:479-487. 10.1083/jcb.91.2.479, 2111958, 6118377.
29. Kamazawa S, Kigawa J, Minagawa Y, Itamochi H, Shimada M, Takahashi M, Sato S, Akeshima R, Terakawa N. Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells. Oncology 2000, 59:329-335. 10.1159/000012191, 11096346.
30. Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, Terakawa N. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 2002, 86:171-176. 10.1006/gyno.2002.6738, 12144824.
31. Egawa C, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001, 95:255-259. 10.1002/1097-0215(20010720)95:4<255::AID-IJC1043>3.0.CO;2-O, 11400119.
32. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002, 1:707-717.
33. Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 2004, 3:460-467.
34. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007, 13:2061-2067. 10.1158/1078-0432.CCR-06-2078, 17404087.
35. Schmidt M, Bremer E, Hasenclever D, Victor A, Gehrmann M, Steiner E, Schiffer IB, Gebhardt S, Lehr HA, Mahlke M, Hermes M, Mustea A, Tanner B, Koelbl H, Pilch H, Hengstler JG. Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br J Cancer 2007, 96:241-247. 10.1038/sj.bjc.6603538, 2359989, 17211474.
36. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002, 20:2319-2326. 10.1200/JCO.2002.08.125, 11981003.
37. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002, 62:1087-1092.
38. Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, Workman P, Jackman AL. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 2006, 5:1197-1208. 10.1158/1535-7163.MCT-05-0445, 16731752.
39. Nishida H, Omori M, Fukutomi Y, Ninomiya M, Nishiwaki S, Suganuma M, Moriwaki H, Muto Y. Inhibitory effects of (-)-epigallocatechin gallate on spontaneous hepatoma in C3H/HeNCrj mice and human hepatoma-derived PLC/PRF/5 cells. Jpn J Cancer Res 1994, 85:221-225.
40. Yin P, Zhao J, Cheng S, Zhu Q, Liu Z, Zhengguo L. Experimental studies of the inhibitory effects of green tea catechin on mice large intestinal cancers induced by 1,2-dimethylhydrazine. Cancer Lett 1994, 79:33-38. 10.1016/0304-3835(94)90059-0, 8187052.
41. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993, 85:1038-1049. 10.1093/jnci/85.13.1038, 8515490.
42. Katiyar S, Mukhtar H. Tea in chemoprevention of cancer: epidemiologic and experimental studies. Int J Oncol 1996, 8:221-238.
43. Sadzuka Y, Sugiyama T, Sonobe T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol Lett 2000, 114:155-162. 10.1016/S0378-4274(99)00290-8, 10713480.
44. Sadzuka Y, Sugiyama T, Hirota S. Modulation of cancer chemotherapy by green tea. Clin Cancer Res 1998, 4:153-156.
45. Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP, Rosengren RJ. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo. Int J Cancer 2008, 122:1966-1971. 10.1002/ijc.23328, 18098290.
46. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H. Synergistic effects of (--)-epigallocatechin gallate with (--)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 1999, 59:44-47.
47. Li M, He Z, Ermakova S, Zheng D, Tang F, Cho YY, Zhu F, Ma WY, Sham Y, Rogozin EA, Bode AM, Cao Y, Dong Z. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev 2007, 16:598-605. 10.1158/1055-9965.EPI-06-0892, 17372258.
48. Yin Z, Henry EC, Gasiewicz TA. (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 2009, 48:336-345. 10.1021/bi801637q, 2701625, 19113837.
49. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 2003, 63:8118-8121.
50. Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, Dou QP. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res 2007, 67:4303-4310. 10.1158/0008-5472.CAN-06-4699, 17483343.
51. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009, 69:1712-1716. 10.1158/0008-5472.CAN-08-3978, 19223530.